Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2832-2843

  Etienne, Marie Christine ^a   Chazal, Maurice ^a   Laurent Puig, Pierre ^a   Magné, Nicolas ^a   Rosty, Christophe ^a   Formento, Jean Louis ^a   Francoual, Mireille ^a   Formento, Patricia ^a   Renée, Nicole ^a   Chamorey, Emmanuel ^a   Bourgeon, André ^a   Seitz, Jean François ^a   Delpero, Jean Robert ^a   Letoublon, Christian ^a   Pezet, Denis ^a   Milano, Gérard ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DENATURING GRADIENT GEL ELECTROPHORESIS; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037096901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.091     Document Type: Article

References (41)

1. Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer
2. Oxaliplatin: A new agent for colorectal cancer
3. 5-Fluorouracil: Forty-plus and still ticking - A review of its preclinical and clinical development
4. Capecitabine
5. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA
6. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
7. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression
8. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase
9. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
10. p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases
11. Quantification of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
12. p53 mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
13. Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients
14. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
15. Thymidylate synthase and drug resistance
16. Thymidylate synthase inhibitor after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
17. Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy
18. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer
19. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
20. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil
21. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
22. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells
23. Intracellular metabolism of 5-formyltetrahydrofolate in human breast and colon cell lines
24. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: Experimental data
25. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracilfolinic acid treatment: Clinical data
26. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
27. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95 (APO-1/Fas) system
28. p53 promotes selection for Fas-medicated apoptotic resistance
29. p53 and chemosensitivity
30. Methods for thymidylate synthase pharmacodynamics: Serial biopsy, free and total TS, FdUMP and dUMP, and H4Pteglu and CH2-H4Pteglu assays
31. Single step LC method for determination of folylpolyglutamate synthetase activity and separation of polyglutamates
32. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
33. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival
34. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
35. Thymidylate synthase pharmacogenetics in colorectal cancer
36. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil
37. Inhibition of mouse thymidylate synthase promoter activity by the wild type p53 tumor suppressor protein
38. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
39. p53 overexpression in head and neck squamous cell carcinoma: Review of the literature
40. Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma